Keyphrases
Psoriasis
100%
Atopic Dermatitis
84%
Eczema
50%
Systemic Sclerosis
44%
Scleroderma
40%
Interleukin-17 (IL-17)
39%
Moderate-to-severe Atopic Dermatitis
38%
Dupilumab
31%
Inflammatory Skin Diseases
30%
T Cells
26%
Atopic Eczema
24%
Interleukin-22 (IL-22)
23%
Keratinocytes
22%
Germany
20%
T Helper 17 (Th17)
20%
Moderate-to-severe Psoriasis
19%
Immune Response
19%
Optoacoustic Mesoscopy
19%
Upadacitinib
19%
Allergy
17%
Guselkumab
16%
Inflammation
15%
Severity Index
15%
Area Index
15%
Psoriasis Pathogenesis
15%
Disease Progression
15%
Generalized Pustular Psoriasis
14%
Fumaric Acid Esters
14%
EUSTAR
14%
Diffuse Cutaneous Systemic Sclerosis
14%
Molecular Diagnostics
14%
Chronic mucocutaneous Candidiasis
13%
Itch
13%
Chronic Inflammatory Skin Disease
12%
Comorbidity
11%
Raster Scanning
11%
Skin Diseases
11%
EAACI
10%
Skin Fibrosis
10%
Risk Factors
10%
Systemic Treatment
10%
Dermatologist
10%
Interleukin-23 (IL-23)
10%
Epidermis
9%
Digital Ulcers
9%
Pruritus
9%
Research Cohort
9%
Autoantibodies
9%
Dermatological Diseases
9%
Modified Rodnan Skin Score (mRSS)
9%
Immunology and Microbiology
Atopic Dermatitis
61%
Eczema
60%
Systemic Scleroderma
46%
Cytokine
46%
Dermatitis
42%
Interleukin 17
40%
T Cell
37%
Keratinocyte
31%
Scleroderma
30%
Immune Response
28%
Infection
16%
Comorbidity
13%
Autoantibodies
12%
Innate Immune System
12%
Dupilumab
12%
Chronic Mucocutaneous Candidiasis
12%
Skin Allergy
11%
Prevalence
11%
Gene Expression
9%
B Cell
9%
Tumor Necrosis Factor
9%
Synovitis
8%
Interleukin 22
8%
Candida
8%
Transcriptomics
8%
Microbiome
8%
Atopy
8%
Immunocompetent Cell
8%
Systemic Inflammation
7%
Th22 Cell
7%
Wound Healing
7%
Secretion (Process)
7%
Th17 Cell
7%
Immunoglobulin E
6%
Toll-Like Receptor
6%
Interleukin 6
6%
Interleukin 4
6%
In Vitro
6%
Patch Test
6%
Interleukin 1
6%
Mediator
6%
Dendritic Cell
6%
Supernatant
6%
Allergen
6%
Biological Product
6%
Immunotherapy
6%
Neutrophil
5%
T Helper 17 Cell
5%
Hapten
5%
Autoimmunity
5%
Medicine and Dentistry
Psoriasis
56%
Atopic Dermatitis
50%
Systemic Scleroderma
43%
Diseases
42%
Dermatology
34%
Eczema
30%
Dermatitis
27%
Scleroderma
25%
Biological Marker
19%
Systemic Therapy
16%
Psoriasis Vulgaris
12%
Interleukin 17
12%
Disease Exacerbation
12%
Infection
11%
Generalized Pustular Psoriasis
11%
Guselkumab
10%
Pruritus
10%
T Cell
10%
Personalized Medicine
10%
Molecular Diagnostics
9%
Dupilumab
9%
Hand Eczema
8%
Disease Duration
8%
Cytokine
8%
Fumaric Acid
8%
Skin Fibrosis
8%
Apremilast
8%
Biological Product
8%
Keratinocyte
7%
Disease Course
7%
Inflammatory Disorder
6%
Finger Ulcer
6%
Synovitis
6%
Dermatosis
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Treatment Response
6%
Disease Severity
6%
Targeted Therapy
6%
Dermatological Disease
5%
Placebo
5%
Clinical Trial
5%
Prospective Study
5%
Prevalence
5%
Lung
5%
Skin Disease
5%
Autoantibodies
5%
Oral
5%
COVID-19
5%
Chronic Urticaria
5%
Mucocutaneous Candidiasis
5%
